Clinical CDMO Opportunity Neobiosis operates as a private, clinical stage CDMO with facilities in Gainesville and an R&D lab in Alachua, focusing on tissues, cells, and extracellular vesicles from perinatal sources. This positions them as a potential partner for biotech and pharma clients seeking GMP-compliant manufacturing and development support for regenerative medicine products and EV-based therapies.

Perinatal Cell & EV Focus Their core expertise in isolating tissues, cells, and extracellular vesicles from donated birth tissues suggests sales opportunities with clients pursuing neonatal or maternal-derived biologics, or regenerative medicine programs that leverage allogeneic cell or EV platforms for clinical trials and potential commercialization.

Geographic & Collaboration Edge With production facilities in downtown Gainesville and a strategic R&D site within the Sid Martin UF Innovate Institute, Neobiosis has proximity to academic and biotechnical ecosystems, enabling co-development, sponsored research, and collaboration agreements that can expedite early-stage programs for biotechs and universities.

Pipeline & IP Potential Neobiosis emphasizes an in-house pipeline of intellectual property and biologics for anti-aging and regenerative medicine, presenting sales touchpoints for partners seeking booleanable IP-enabled platforms, exclusive collaborations, or development rights to proprietary biologics and related manufacturing processes.

Financial Context Reported revenue in the range of $10M-$25M, coupled with a modest employee base, indicates a lean, specialized CRO/CDMO setup with potential for scalable manufacturing partnerships, clinical trial supply contracts, and pilot projects for mid-sized biotech firms looking for nimble, focused manufacturing partners.